Latest Cell Therapy News

Page 5 of 9
INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.
Ada Torres
Ada Torres
31 July 2025
Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.
Ada Torres
Ada Torres
30 July 2025
PolyNovo Limited reports a robust FY25 with nearly 29% sales growth, a significant cash increase to A$33.5 million, and expanding global market presence. The company’s strategic investments and product innovations signal strong momentum ahead.
Ada Torres
Ada Torres
29 July 2025
Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.
Ada Torres
Ada Torres
29 July 2025
Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.
Ada Torres
Ada Torres
29 July 2025
Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.
Ada Torres
Ada Torres
28 July 2025
NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.
Ada Torres
Ada Torres
28 July 2025
NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.
Ada Torres
Ada Torres
23 July 2025
AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.
Ada Torres
Ada Torres
23 July 2025
Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.
Ada Torres
Ada Torres
22 July 2025
Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.
Ada Torres
Ada Torres
18 July 2025
Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.
Ada Torres
Ada Torres
16 July 2025